218770-02-6Relevant articles and documents
GPR119 Receptor Agonists
-
Page/Page column 19, (2009/12/05)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: Effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice
Holladay, Mark W.,Bai, Hao,Li, Yihong,Lin, Nan-Horng,Daanen, Jerome F.,Ryther, Keith B.,Wasicak, James T.,Kincaid, John F.,He, Yun,Hettinger, Anne-Marie,Huang, Peggy,Anderson, David J.,Bannon, Anthony W.,Buckley, Michael J.,Campbell, Jeffrey E.,Donnelly-Roberts, Diana L.,Gunther, Karen L.,Kim, David J. B.,Kuntzweiler, Theresa A.,Sullivan, James P.,Decker, Michael W.,Arneric, Stephen P.
, p. 2797 - 2802 (2007/10/03)
Analogs of A-98593 (1) and its enantiomer ABT-594 (2) with diverse substituents on the pyridine ring were prepared and tested for affinity to nicotinic acetylcholine receptor binding sites in rat brain and for analgesic activity in the mouse hot plate assay. Numerous types of modifications were consistent with high affinity for [3H]cytisine binding sites. By contrast, only selected modifications resulted in retention of analgesic potency in the ame range as 1 and 2. Analogs of 2 with one or two methyl substituents at the 3-position of the azetidine ring also were prepared and found to be substantially less active in both assays.